Application of medicine combination in preparing preparation for treating chronic hepatitis B

A technology for chronic hepatitis B and a composition is applied in the application field of preparing preparations for treating chronic hepatitis B, and can solve the problems of repeated disease, HBV mutation, drug resistance and the like

Active Publication Date: 2010-01-20
JIUZHITANG
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although lamivudine has a good curative effect in the treatment of chronic hepatitis B, long-term use of patients will produce HBV mutations, and the longer the course of treatment, the higher the incidence of mutations, resulting in drug resistance and recurrence of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of medicine combination in preparing preparation for treating chronic hepatitis B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The BCG polysaccharide nucleic acid required by the present invention can be obtained by the following methods, but those skilled in the art can understand that the preparation of BCG polysaccharide nucleic acid includes but is not limited to this method:

[0021] 1) Cultivation and harvest of BCG

[0022] 1. Bacterial culture: Dissolve the strains preserved in liquid cryogenic temperature (BCG strain D2PB302 for the preparation of BCG in China, China National Institute for the Control of Pharmaceutical and Biological Products) at room temperature, inoculate in potato Sutong culture medium, and culture continuously at 37°C for 14-20 days ; or after continuous cultivation at 37°C for 15 days, transfer to improved liquid Sutong medium, and continuous cultivation at 37°C for 14-20 days.

[0023] 2. Bacteria collection: When the bacteria grow to the logarithmic phase, check the culture bottles one by one, collect the bacteria film, add an appropriate amount of deionized dis...

Embodiment 2

[0040] A kind of production method of the pharmaceutical composition injection for the treatment of chronic hepatitis B, prescription is:

[0041] BCG nucleic acid: 0.3g

[0042] Physiological sodium chloride solution (0.9%): 100ml

[0043] Take the ordinary freeze-dried powder D BCG polysaccharide nucleic acid of prescription quantity and mix uniformly with appropriate amount of water for injection, and those skilled in the art can also understand that the BCG polysaccharide nucleic acid can be obtained in the form of micropowder, solid dispersion, clathrate, microsphere, Add in the form of liposomes or microparticles. After fully dissolving, centrifuge at a speed of 4000 rpm and 3°C for 15 minutes. Take the supernatant and test the content of polysaccharides and nucleic acids. After the test is qualified, the supernatant passes through 0.22 Finely filter with a μm filter, then fill and seal in an ampoule, and sterilize by high-pressure steam to obtain the injection.

Embodiment 3

[0045] A kind of production method of the pharmaceutical composition powder injection for treating chronic hepatitis B, prescription is:

[0046] BCG nucleic acid: 0.3g

[0047] Physiological sodium chloride solution (0.9%): 100ml

[0048]Take the ordinary freeze-dried powder D BCG polysaccharide nucleic acid of prescription quantity and mix uniformly with appropriate amount of water for injection, and those skilled in the art can also understand that the BCG polysaccharide nucleic acid can be obtained in the form of micropowder, solid dispersion, clathrate, microsphere, Add in the form of liposomes or microparticles. After fully dissolving, centrifuge at a speed of 4000 rpm and 3°C for 15 minutes. Take the supernatant and test the content of polysaccharides and nucleic acids. After the test is qualified, the supernatant passes through 0.22 The μm filter is used for fine filtration, and the filtrate is sterilized by high-pressure steam, then packed into vials, freeze-dried, p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the application of a medicine combination in preparing a preparation for treating chronic hepatitis B. The medicine combination uses polysaccharide nucleic acid of bacillus calmette Guerin as the active component; the polysaccharide nucleic acid of bacillus calmette Guerin is a nonspecific immunity active reinforcer, and can effectively restrain the reproduction of hepatitis virus and promote the rapid negative turning of HBV-DNA and HbeA. The invention has the advantages of low price, high safety, high adaptability, rapid effect, long effect maintenance time and low drug resistance in treating the chronic hepatitis B.

Description

technical field [0001] The present invention relates to an application of a pharmaceutical composition, in particular to its application in preparing preparations for treating chronic hepatitis B Background technique [0002] Chronic hepatitis B (HBV) infection is a global health problem. It is estimated that about 350 million people in the world are infected with hepatitis B virus, of which 75% live in the Asia-Pacific region. In my country, about 120 million people are carriers of hepatitis B virus. 28 million, the prevalence rate is as high as 2770 / 100,000, and one-third of hepatitis B patients will develop into chronic hepatitis, cirrhosis or liver cancer. In 1998, about 2 million people died of liver cancer caused by viruses in the world, and the death toll in my country was 300,000. The World Health Organization has listed hepatitis B as the ninth leading cause of death in the world. Moreover, once people are infected with hepatitis virus, they must take medicine for a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61P1/16A61P31/20
Inventor 宁云山关继峰张燚
Owner JIUZHITANG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products